<DOC>
	<DOCNO>NCT01913535</DOCNO>
	<brief_summary>This study look efficacy , rapidity , safety , tolerability two dose oral CERC-501 treating patient treatment resistant depression take antidepressant working .</brief_summary>
	<brief_title>Proof-of-Concept Trial CERC-501 Augmentation Antidepressant Therapy Treatment-Resistant Depression</brief_title>
	<detailed_description>This study involve 10 visit clinical site approximately 1.5 month . There screen visit ( 7-28 day may pass screen visit first treatment visit ) , baseline/treatment visit ( first day study drug treatment ) , follow 5 consecutive day treatment visit . Follow-up visit occur 6 , 13 , 20 day first receive study drug .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Male female , 1865 year old . Able read , understand , provide write , date informed consent prior screen . Diagnosed Major Depressive Disorder ( MDD ) , single recurrent , currently experience Major Depressive Episode ( MDE ) least eight week duration , prior screen . Has history treatment resistance current MDE . Meet threshold total MADRS score great equal 20 screen baseline visit , confirm remote centralize MGH CTNI rater screen visit baseline visit . In good general health For female participant , status nonchildbearing potential use acceptable form birth control Body mass index 1840 kg/m2 Concurrent psychotherapy allow type frequency therapy stable least three month prior screen expect remain stable participation study Concurrent benzodiazepine hypnotic therapy allow therapy stable least 4 week prior screen expect remain stable course subject 's participation study . Female childbearing potential willing use one specify form birth control study Female pregnant breastfeed Female positive pregnancy test screen baseline History current MDE failure achieve satisfactory response &gt; 3 treatment course therapeutic dose antidepressant therapy least 8 week duration current episode Total MADRS score &lt; 20 screen baseline visit , assessed remote , independent MGH CTNI rater report site Current diagnosis Substance Use Disorder ( Abuse Dependence ) exception nicotine dependence , screen within six month prior screen Current diagnosis Axis I disorder Dysthymic Disorder , Generalized Anxiety Disorder , Social Anxiety Disorder , Panic Disorder Specific Phobia ( unless one comorbid clinically unstable , and/or focus participant 's treatment past 6 month ) History bipolar disorder , schizophrenia schizoaffective disorder , history psychotic symptom current previous depressive episode History eat disorder within five year screen Any Axis I Axis II Disorder , screen clinically predominant MDD predominant time within 6 month prior screen Subject consider significant risk suicidal behavior course participation study Subject electroconvulsive therapy current episode depression Has receive vagus nerve stimulation ( VNS ) time prior screen Dementia , delirium , amnestic , cognitive disorder Has clinically significant abnormality screen physical examination Participation clinical trial investigational drug device within past month concurrent study participation Known history current episode : Uncontrolled hypertension , Recent myocardial infarction ( within one year ) history one myocardial infarction , Syncopal event within past year , Congestive heart failure , Angina pectoris , Systolic BP &lt; 85 &gt; 160 mmHg diastolic BP &gt; 95 mmHg heart rate &lt; 50 &gt; 105 beat per minute screen randomization , QTcF great equal 450 msec screen randomization . Chronic lung disease Lifetime history surgical procedure involve brain meninges , encephalitis , meningitis , degenerative central nervous system disorder , epilepsy , mental retardation , disease/procedure/accident/intervention associate significant injury malfunction central nervous system , history significant head trauma within past 2 year Presents history Thyroid stimulate hormone outside normal limit clinically significant determined investigator Patients diabetes mellitus fulfil follow criterion : 1 . Unstable diabetes mellitus define glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % screen 2 . Admitted hospital treatment diabetes mellitus diabetes mellitus related illness past 12 week 3 . Not physician care diabetes mellitus 4 . Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior screen . For thiazolidinediones ( glitazones ) period le 8 week . 5 . Any clinically significant abnormal laboratory result ( determine evaluation study investigator MGH CTNI medical monitor ) time screen exam . History hypothyroidism stable dosage thyroid replacement medication , surgically treat less six month prior screen History hyperthyroidism treat ( medically surgically ) less six month prior screen Any current past history physical condition investigator 's opinion might put subject risk interfere interpretation study result History positive screening urine test drug abuse Patients exclusionary laboratory value , require treatment exclusionary concomitant medication , include tricyclic antidepressant monoamine oxidase inhibitor , two concomitant antidepressant therapy Patients currently take proton pump inhibitor ( PPI ) /histamine 2 ( H2 ) blocker history chronic NSAID use Patients positive test Helicobacter pylorus ( urea breath test ) Patients follow GIrelated finding : 1 . Clinically evident GI complaint GI disease Screening Visit 1 2 . Past history gastric disease ( include limit peptic ulcer disease , gastritis ( include atrophic gastritis ) , upper GI bleeding , GI precancerous condition ) , clinically relevant GI disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Major Depression</keyword>
	<keyword>MDD</keyword>
</DOC>